1

UNITAID

Innovation for Global Health

May 6th, 2016, Geneva

2

Innovation for Global Health

UNITAID was created in 2006 as part of the global response to HIV/AIDS,

Tuberculosis and Malaria by the governments of Brazil, Chile, France, Norway

and the United Kingdom as the “International Drug Purchasing Facility.”

Today it is backed by an expanding “North-South” membership, including

Cyprus, Korea, Luxembourg, Spain and the Bill & Melinda Gates Foundation

alongside Cameroon, Congo, Guinea, Madagascar, Mali, Mauritius and Niger.

Civil society groups also govern UNITAID, giving a voice to non-governmental

organizations and communities living with HIV, malaria and tuberculosis.

UNITAID is part of the Global Response to bring new, better, faster and more

affordable medicines and technologies to those in need.

3

Innovative Financing

UNITAID Uses Innovative Financing to solve market inefficiencies such as

gaps in the price, quality, availability, acceptability and/or delivery of health

products. Through innovative financing UNITAID attempts to meet these needs

and contribute to the global response to bring new, better, faster and more

affordable medicines and technologies and systems to those in need.

UNITAID has raised over half of its funds in the last five years through the 'air

ticket levy .‘

Nine countries have implemented the air ticket levy: Cameroon, Chile, Congo,

France, Madagascar, Mali, Mauritius, Niger and the Republic of Korea. Norway

allocates part of its tax on CO2 emissions. The air ticket levy promotes South–

South cooperation by allowing new actors from Africa and Latin America to

participate in financing international development.

4

Revenue since inception $2.4 b

5

Revenue for 2014 $249 m

6

UNITAID is part of the global response

0

10,000

20,000

30,000

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Material and child

Health Initiative (2010)

Joint Health System

Platform (2009)

Accra Action Agenda on

Aid effectiveness (2008)

International Health

Partnership (2007)

UNITAID

(2006)

Development Assistance for Health ($M)

Paris Declaration on

Aid Effectiveness (2005)

US President’s

Emergency Plan for AIDS

Relief PEPFAR (2003)

Global Fund for AIDS, TB

and malaria (2002) Stop TB

Partnership

(2001)

Global Alliance for Vaccines

and Immunization (2000)

Bill Melinda Gates

Foundation (1999) Roll Back

Malaria

(1998)

Global advocacy

movement

Innovative partnership

creation

Millennium

Development

Goals (2001)

Monterrey

Consensus on

Development

Finance (2002)

Partnership development

and effectiveness

Source: D Low-Beer, Distribution of Development Assistance for Health

7

Notable achievements in past 15 years, but a long way to

go

Major results have been achieved... ... but still a long way to go

10

0

20

People under ART in LMIC (M)

x 19

13.0

0.7

2004

Global ART

coverage

37%

63%

62%

38%

70

60

50

40

Case detection rate in high burden countries (%)

830639 584

1 000

500

0

-30%

Estimated # deaths (1,000)

2015

>3M missed TB cases

in 2013

~22M people still need

treatment in 2015

MDR-TB crisis

2000 2005 2010 2013

2005 2010 2013

<40% patients

receiving ACTs

<50% use of vector

control in Africa

Source: UNAIDS 2014 "90-90-90", END TB post-2015 Strategy, Malaria Draft Global Technical Strategy: post-2015 (World Health Assembly, March 2015)

8

UNITAID's role in global response By connecting the upstream to the downstream... and enabling others to do more with less

Upstream

Downstrea

m HIV / AIDS Tuberculosis Malaria

PDPs BMGF Industry Academia ...others... Grand

Challenges

Government

s & Partners

Regulatory Evidence

Quality

Devices

Adaptabilit

y

Price

Medicines Systems

IP Market

intervention

s

with

grantees

9

UNITAID's current investments map to global goals

Disease Global Goals Challenges Opportunities

Selection of UNITAID

projects

HIV / AIDS

By 2020:

90% know status

90% on treatment

90% virally

suppressed

Only 50% know status

Only 38% on Tx

Only 25% have access to VL

Cheaper & new tools

Better formulations for

LMICs, esp. children

New tools + evidence

generation

TB By 2035:

90% reduction in

new cases

95% reduction in

deaths

Lack of drug sensitivity

testing

Lack of POC, near-POC Dx

Lack of ped. formulations

Fragmented & small markets

Lack of MDR-testing

New tools for

underserved

populations

Better formulations for

children

Demand consolidation

Support for supply

Malaria

By 2030:

Universal access to

case mgmt

90% reduction in

incidence

90% reduction in

mortality

Elimination from

35+ countries

RDTs: poor quality-

assurance, lack in private

sector

Lack of severe malaria

treatments

Lack of seasonal malaria

prevention

Concerns over resistance

New RDTs,

development of private

sector market,

evidence-generation

Child-friendly solutions

New insecticides,

vector control & better

supply coordination

• New self & oral Dx

• Early Infant Device

• Lower cost & innovative Tx ,

incl. for HCV co-infected

•

• CD4 + VL Dx

• Expanded access to QA TB Dx

•

• Better pediatric meds

• Increased access to 2nd-line

MDR-TB meds

• Creation of private sector RDT

market

• Global & national QA

• Severe malaria programs

•

• SMC in Sahel

GeneXpert

Note: does not include all projects, such as those that are completed or under consideration (as of Mar 2015) Source: UNAIDS 2014 "90-90-90", END TB post-2015 Strategy, Malaria Draft Global Technical Strategy: post-2015 (World Health Assembly, March 2015)

10

HIV Portfolio Strategic investment mapping

~35% 42%

2015 2017

11

~31% 27%

2015 2017

Tuberculosis Portfolio Strategic investment mapping

12

Strategic investment mapping

Malaria Portfolio

~21% 23%

2015 2017

13

Transversal Portfolio Strategic investment mapping

~14% 8%

2015 2017

14

Partner engagement How have we been engaging partners to secure impact?